A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs IONIS-HBV-LRx (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline
- 06 Sep 2017 Planned number of patients changed from 120 to 150.
- 06 Sep 2017 Planned End Date changed from 12 Feb 2018 to 28 Jan 2019.
- 06 Sep 2017 Planned primary completion date changed from 12 Feb 2018 to 4 Nov 2018.